What question did this study set out to answer?

To explore how multidimensional functional status influences treatment selection and outcomes in tAML and AML MRC patients.

December 8, 2025Blood

Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

Multicenter cohort study shows venetoclax-based low-intensity chemotherapy improved survival in tAML patients with functional impairments.

To explore how multidimensional functional status influences treatment selection and outcomes in tAML and AML MRC patients.
Enrolled patients ≥18 years with newly diagnosed tAML or AML MRC in a prospective cohort study across 6 centers.
Assessed multidimensional functional status including physical, cognitive function, and HRQOL at baseline and 1 and 3 months.
Evaluated therapy selection and followed patients for disease status and survival.
54% received low-intensity chemotherapy, while 46% received intensive chemotherapy.
Survival at 30 days was 94.4%, and 52.2% at 1 year.
Many survivors showed stabilization or improvement in functional measures such as ADL, IADL and depression scores within 3 months.

Maakaron et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Multicenter cohort study shows venetoclax-based low-intensity chemotherapy improved survival in tAML patients with functional impairments.